# SIRT6 positions Genflow Biosciences in a high-value area of longevity research

- Link: https://www.directorstalkinterviews.com/sirt6-positions-genflow-biosciences-in-a-high-value-area-of-longevity-research/4121256347
- Published: 2026-07-17T09:20:00+01:00
- Author: Amilia Stone

The SIRT6 gene plays a central role in DNA repair, metabolism and cellular ageing.
It produces an enzyme that helps protect genetic material, regulate energy use and
maintain chromosome stability. These functions make SIRT6 a significant target in
the development of treatments for age-related disease.

Genflow Biosciences is focused on the therapeutic potential of SIRT6 because the
gene acts across several biological pathways linked to declining health. Rather 
than addressing a single symptom or disease, SIRT6 may offer a way to influence 
some of the underlying mechanisms associated with ageing.

A key function of SIRT6 is DNA repair. Cells are exposed to constant genetic damage,
including double-strand breaks that can disrupt normal function. SIRT6 moves to 
damaged areas of DNA and helps recruit the proteins needed to carry out repairs.
This limits the accumulation of genetic errors and supports long-term cellular stability.

Poor DNA repair is linked to ageing, cancer and other chronic conditions. A treatment
that strengthens this process could have applications across several large therapeutic
markets.

SIRT6 also regulates how cells use glucose and fats. It helps prevent excessive 
glycolysis and supports balanced energy production. Metabolic dysfunction is closely
connected with age-related decline and several common diseases.

By influencing both DNA maintenance and metabolism, SIRT6 offers a broader therapeutic
profile than many single-pathway targets. That breadth creates opportunity, but 
it also increases development complexity. Any treatment must deliver the right level
of activity in the right tissues without disrupting normal cell function.

Animal studies support the scientific case. Increased SIRT6 activity has extended
lifespan in mice, while SIRT6 deficiency has caused developmental problems and signs
of accelerated ageing. These findings strengthen the rationale for further development,
although they do not confirm that the same results will occur in humans.

SIRT6 is also relevant to cancer research. Lower levels of the enzyme are often 
associated with tumour progression and impaired metabolic control. Its role in regulating
DNA repair, cell growth and energy use means it could support future approaches 
in oncology as well as longevity medicine.

_**[Genflow Biosciences plc](https://www.directorstalkinterviews.com/company/genflow-biosciences-plc/genf.l)**(
LON:GENF, OTCQB:GENFF, FRA:WQ5) is a UK-based biotech firm with R&D facilities in
Belgium focused on developing novel therapeutic approaches that potentially halt
or slow the aging process in humans and dogs supporting longer, healthier lives_

Share on: